Moderna Inc (MRNA) Stock Analysis
$MRNA · HEALTHCARE · BIOTECHNOLOGY · NASDAQ
Moderna (MRNA), a BIOTECHNOLOGY company, is listed on NASDAQ and has a market capitalization of about $87.04B.
Price
$218.01
Market cap
$87.04B
Dividend yield
—
About Moderna Inc
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
How StockWorthy values MRNA
StockWorthy forecasts Moderna Inc's revenue, operating profitability, reinvestment (capital expenditure, depreciation and working capital) and unlevered free cash flow, then discounts those cash flows using a normalized cost of capital built from MRNA's size, profitability and balance-sheet risk. Terminal growth is adjusted to reflect the company's mature growth profile rather than a fixed number. The model presents bear, base and bull scenarios, and every key assumption stays transparent and adjustable in the full StockWorthy analysis. Results are educational and not investment advice.
Related stocks
See MRNA's Fair Value
Create a free account to view Moderna Inc's base-case fair value, the bear–bull modeled range, and every assumption behind them. Free accounts include 5 stock valuations per month — plus Advanced DCF models, financial charts, dividends, and peer analysis.